UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended SeptemberJune 30, 20222023

OR

☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

 

Commission file number:0-20852

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation of organization)

2000 Technology Parkway Newark, New York 14513

(Address of principal executive offices) (Zip Code)

16-1387013

(I.R.S. Employer Identification No.)

(315) 332-7100 

(Registrant’s telephone number, including area code:)code)

 

None

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.10 par value per share

ULBI

NASDAQ

(Title of each class)

(Trading Symbol)

(Name of each exchange on which registered)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filefile required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer

  

Non-accelerated filer

Smaller reporting company ☒

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No☒

 

As of OctoberJuly 24, 2022,2023, the registrant had 16,133,61816,150,693 shares of common stock outstanding.

 



 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

 

INDEX

         

  

Page

PART I.

FINANCIAL INFORMATION

 
   

Item 1.

Consolidated Financial Statements (unaudited):

 
   
 

Consolidated Balance Sheets as of SeptemberJune 30, 20222023 and December 31, 20212022

1

   
 

Consolidated Statements of (Loss) Income and Comprehensive Income (Loss) Income for the Three and Nine-MonthSix-Month Periods Ended SeptemberJune 30, 20222023 and SeptemberJune 30, 20212022

2

   
 

Consolidated Statements of Cash Flows for the Nine-MonthSix-Month Periods Ended SeptemberJune 30, 20222023 and SeptemberJune 30, 20212022

3

   
 

Consolidated Statements of Changes in Stockholders’Shareholders’ Equity for the Three and Nine-MonthSix-Month Periods Ended SeptemberJune 30, 20222023 and SeptemberJune 30, 20212022

4

   
 

Notes to Consolidated Financial Statements (unaudited)

5

   

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

2016

   

Item 4.

Controls and Procedures

2925

   

PART II.

OTHER INFORMATION

 
   
Item 1A.Risk Factors30

Item 6.

Exhibits

3026

   
 

Signatures

3127

 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. CONSOLIDATED FINANCIAL STATEMENTS

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Thousands except share amounts)

(Unaudited)

 

 
 
 

September 30,

2022

  

December 31,
2021

  

June 30,

2023

  

December 31,

2022

 
ASSETS ASSETS 
Current assets:  

Cash

 $5,051  $8,413  $8,283  $5,713 

Trade accounts receivable, net of allowance for doubtful accounts of $305 and $346, respectively

 26,876  20,232 

Trade accounts receivable, net of allowance for expected credit losses of $288 and $303, respectively

 28,630  27,779 

Inventories, net

 40,769  33,189  46,063  41,192 

Prepaid expenses and other current assets

  6,241   4,690   4,850   4,304 

Total current assets

 78,937  66,524  87,826  78,988 

Property, plant and equipment, net

 21,898  23,205  21,122  21,716 

Goodwill

 37,066  38,068  37,501  37,428 

Other intangible assets, net

 16,095  17,390  15,552  15,921 

Deferred income taxes, net

 11,963  11,472  11,084  12,069 

Other noncurrent assets

  1,981   2,879   2,307   2,308 

Total assets

 $167,940  $159,538  $175,392  $168,430 
  

LIABILITIES AND STOCKHOLDERS EQUITY

 

LIABILITIES AND SHAREHOLDERS EQUITY

LIABILITIES AND SHAREHOLDERS EQUITY

 
Current liabilities:  

Accounts payable

 $15,827  $9,823  $18,541  $16,074 

Current portion of long-term debt

 2,000  2,000  2,000  2,000 

Accrued compensation and related benefits

 2,000  1,842  2,320  2,890 

Accrued expenses and other current liabilities

  8,254   5,259   6,342   7,949 

Total current liabilities

 28,081  18,924  29,203  28,913 

Long-term debt, net

 20,874  18,857 

Long-term debt

 22,642  19,310 

Deferred income taxes

 1,996  2,254  1,876  1,917 

Other noncurrent liabilities

  1,673   1,760   1,996   1,887 

Total liabilities

  52,624   41,795   55,717   52,027 
  
Commitments and contingencies (Note 9) 
Commitments and contingencies (Note 8) 
  
Stockholders’ equity: 
Shareholders’ equity: 

Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued

 -  -  -  - 

Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 20,568,210 shares at September 30, 2022 and 20,522,427 shares at December 31, 2021; outstanding – 16,133,618 shares at September 30, 2022 and 16,089,832 shares at December 31, 2021

 2,057  2,052 

Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 20,586,045 shares at June 30, 2023 and 20,570,710 shares at December 31, 2022; outstanding – 16,150,693 shares at June 30, 2023 and 16,135,358shares at December 31, 2022

 2,059  2,057 

Capital in excess of par value

 187,181  186,518  187,758  187,405 

Accumulated deficit

 (47,727) (47,832) (44,957) (47,951)

Accumulated other comprehensive loss

 (4,842) (1,653) (3,846) (3,750)

Treasury stock - at cost; 4,434,592 shares at September 30, 2022 and 4,432,595 shares at December 31, 2021

  (21,480)  (21,469)

Treasury stock - at cost; 4,435,352 shares at June 30, 2023 and 4,435,352 shares at December 31, 2022

  (21,484)  (21,484)

Total Ultralife Corporation equity

 115,189  117,616  119,530  116,277 

Non-controlling interest

  127   127   145   126 

Total stockholders’ equity

  115,316   117,743 

Total shareholders’ equity

  119,675   116,403 
  

Total liabilities and stockholders’ equity

 $167,940  $159,538 

Total liabilities and shareholders’ equity

 $175,392  $168,430 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME AND COMPREHENSIVE INCOME (LOSS) INCOME

(In thousands except per share amounts)

(Unaudited)

 

 

Three-month period ended

  

Nine-month period ended

  

Three-month period ended

  

Six-month period ended

 
 

September 30,

2022

  

September 30,

2021

  

September 30,

2022

  

September 30,

2021

  

June 30,

2023

  

June 30,

2022

  

June 30,

2023

  

June 30,

2022

 
  

Revenues

 $33,234  $21,761  $95,733  $74,504  $42,692  $32,126  $74,608  $62,499 

Cost of products sold

  26,519   16,653   74,414   55,151   32,104   24,480   56,584   47,895 

Gross profit

  6,715   5,108   21,319   19,353   10,588   7,646   18,024   14,604 
  
Operating expenses:                

Research and development

 1,896  1,723  5,425  5,223  1,778  1,672  3,810  3,529 

Selling, general and administrative

  5,405   4,164   15,982   12,866   5,145   5,181   10,523   10,577 

Total operating expenses

  7,301   5,887   21,407   18,089   6,923   6,853   14,333   14,106 
  

Operating (loss) income

 (586) (779) (88) 1,264 

Operating income

 3,665  793  3,691  498 
  
Other (income) expense:        

Other income (expense):

        

Interest and financing expense

 272  53  583  164  (440) (177) (864) (311)

Miscellaneous

  (526)  (54)  (605)  (88)

Total other (income) expense

  (254)  (1)  (22)  76 

Miscellaneous income

  1,498   62   1,428   79 

Total other income (expense)

  1,058   (115)  564   (232)
  

(Loss) income before income taxes

 (332) (778) (66) 1,188 

Income tax (benefit) provision

  (90)  (175)  (171)  290 

Income before income taxes

 4,723  678  4,255  266 

Income tax provision (benefit)

  1,375   170   1,242   (81)
  

Net (loss) income

 (242) (603) 105  898 

Net income

 3,348  508  3,013  347 
  

Net (loss) income attributable to non-controlling interest

  (3)  (18)  -   1 

Net income (loss) attributable to non-controlling interest

  8   (4)  19   3 
  

Net (loss) income attributable to Ultralife Corporation

 (239) (585) 105  897 

Net income attributable to Ultralife Corporation

 3,340  512  2,994  344 
  
Other comprehensive loss:                

Foreign currency translation adjustments

  (1,691)  (233)  (3,189)  (37)  (293)  (1,262)  (96)  (1,498)
  

Comprehensive (loss) income attributable to Ultralife Corporation

 $(1,930) $(818) $(3,084) $860 

Comprehensive income (loss) attributable to Ultralife Corporation

 $3,047  $(750) $2,898  $(1,154)
  

Net (loss) income per share attributable to Ultralife common stockholders basic

 $(.01) $(.04) $.01  $.06 

Net income per share attributable to Ultralife common stockholders basic

 $.21  $.03  $.19  $.02 
  

Net (loss) income per share attributable to Ultralife common stockholders diluted

 $(.01) $(.04) $.01  $.06 

Net income per share attributable to Ultralife common stockholders diluted

 $.21  $.03  $.19  $.02 
  

Weighted average shares outstanding basic

 16,133  16,065  16,122  16,020  16,141  16,129  16,138  16,116 

Potential common shares

  -   -   22   180   3   20   3   25 

Weighted average shares outstanding - diluted

  16,133   16,065   16,144   16,200   16,144   16,149   16,141   16,141 

 

The accompanying notes are an integral part of these consolidated financial statements.

 


 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands)

(Unaudited)

 

 

Nine-month period ended

  

Six-month period ended

 
 

September 30,

2022

  

September 30,

2021

  

June 30,

2023

  

June 30,

2022

 

OPERATING ACTIVITIES:

        

Net income

 $105  $898  $3,013  $347 
Adjustments to reconcile net income to net cash (used in) provided by operating activities: 
Adjustments to reconcile net income to net cash provided by (used in) operating activities: 

Depreciation

 2,450  2,160  1,522  1,635 

Amortization of intangible assets

 969  458  436  651 

Amortization of financing fees

 25  78  32  17 

Stock-based compensation

 552  512  293  373 

Deferred income taxes

 (683) 127  888  (375)
Changes in operating assets and liabilities:  

Accounts receivable

 (7,433) 4,814  (803) (2,385)

Inventories

 (8,714) 17  (4,882) (6,606)

Prepaid expenses and other assets

 (1,004) 775  (526) 104 

Accounts payable and other liabilities

  9,906   (1,377)  413   2,839 

Net cash (used in) provided by operating activities

  (3,827)  8,462 

Net cash provided by (used in) operating activities

  386   (3,400)
  
INVESTING ACTIVITIES:        

Purchases of property, plant and equipment

  (1,396)  (2,324)  (1,013)  (585)

Net cash used in investing activities

  (1,396)  (2,324)  (1,013)  (585)
  
FINANCING ACTIVITIES:        

Borrowings on revolving credit facility

 3,350  -  4,300  1,550 

Payments on term loan facility

 (1,333) (1,186) (1,000) (833)

Proceeds from exercise of stock options

 116  398  62  113 

Payment of debt issuance costs

 (25) -  -  (25)

Tax withholdings on stock-based awards

  (11)  (148)  -   (11)

Net cash provided by (used in) financing activities

  2,097   (936)

Net cash provided by financing activities

  3,362   794 
  

Effect of exchange rate changes on cash

  (236)  (2)  (165)  (108)
  

(DECREASE) INCREASE IN CASH

 (3,362) 5,200 

INCREASE (DECREASE) IN CASH

 2,570  (3,299)
  

Cash, Beginning of period

  8,413   10,653   5,713   8,413 

Cash, End of period

 $5,051  $15,853  $8,283  $5,114 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY

(In thousands except share amounts)

(Unaudited)

 

         

Capital

 

Accumulated

                         

Capital

 

Accumulated

                
 

Common Stock

 

in Excess

 

Other

         

Non-

     

Common Stock

 

in Excess

 

Other

         

Non-

    
 

Number of

     

of Par

 

Comprehensive

 

Accumulated

 

Treasury

 

Controlling

     

Number of

     

of Par

 

Comprehensive

 

Accumulated

 

Treasury

 

Controlling

    
 

Shares

  

Amount

  

Value

  

Income (Loss)

  

Deficit

  

Stock

  

Interest

  

Total

  

Shares

  

Amount

  

Value

  

Income (Loss)

  

Deficit

  

Stock

  

Interest

  

Total

 
                  

Balance December 31, 2020

 20,373,519  $2,037  $185,464  $(1,782) $(47,598) $(21,321) $123  $116,923 

Balance December 31, 2021

 20,522,427  $2,052  $186,518  $(1,653) $(47,832) $(21,469) $127  $117,743 

Net income

          344     3  347 

Stock option exercises

 38,369  4  109       (7)    106 

Stock-based compensation – stock options

      362           362 

Stock-based compensation - restricted stock

      11           11 

Vesting of restricted stock

 6,664  1  (1)      (4)    (4)

Foreign currency translation adjustments

            (1,498)            (1,498)

Balance June 30, 2022

  20,567,460  $2,057  $186,999  $(3,151) $(47,488) $(21,480) $130  $117,067 
 

Balance December 31, 2022

 20,570,710  $2,057  $187,405  $(3,750) $(47,951) $(21,484) $126  $116,403 

Net income

          2,994     19  3,013 

Stock option exercises

 15,335  2  60       -     62 

Stock-based compensation – stock options

      291           291 

Stock-based compensation -restricted stock

      2           2 

Foreign currency translation adjustments

            (96)            (96)

Balance June 30, 2023

  20,586,045  $2,059  $187,758  $(3,846) $(44,957) $(21,484) $145  $119,675 
 

Balance March 31, 2022

 20,560,796  $2,056  $186,816  $(1,889) $(48,000) $(21,476) $134  $117,641 

Net income

          897     1  898           512     (4) 508 

Stock option exercises

 127,324  13  385       (133)    265  -  -  -       -     - 

Stock-based compensation – stock options

      468           468       181           181 

Stock-based compensation -restricted stock

      44           44       3           3 

Vesting of restricted stock

 12,501  1  (1)      (15)    (15) 6,664  1  (1)      (4)    (4)

Foreign currency translation adjustments

            (37)            (37)            (1,262)            (1,262)

Balance September 30, 2021

  20,513,344  $2,051  $186,360  $(1,819) $(46,701) $(21,469) $124  $118,546 

Balance June 30, 2022

  20,567,460  $2,057  $186,999  $(3,151) $(47,488) $(21,480) $130  $117,067 
                  

Balance December 31, 2021

 20,522,427  $2,052  $186,518  $(1,653) $(47,832) $(21,469) $127  $117,743 

Balance March 31, 2023

 20,570,710  $2,057  $187,544  $(3,553) $(48,297) $(21,484) $137  $116,404 

Net income

          105     -  105           3,340     8  3,348 

Stock option exercises

 39,119  4  112       (7)    109  15,335  2  60       -     62 

Stock-based compensation – stock options

      538           538       153           153 

Stock-based compensation -restricted stock

      14           14 

Vesting of restricted stock

 6,664  1  (1)      (4)    (4)

Stock-based compensation - restricted stock

      1           1 

Foreign currency translation adjustments

            (3,189)            (3,189)            (293)            (293)

Balance September 30, 2022

  20,568,210  $2,057  $187,181  $(4,842) $(47,727) $(21,480) $127  $115,316 
                 

Balance June 30, 2021

 20,474,676  $2,047  $186,138  $(1,586) $(46,116) $(21,388) $142  $119,237 

Net loss

          (585)    (18) (603)

Stock option exercises

 38,668  4  80       (81)    3 

Stock-based compensation – stock options

      131           131 

Stock-based compensation -restricted stock

      11           11 

Vesting of restricted stock

                 

Foreign currency translation adjustments

            (233)            (233)

Balance September 30, 2021

  20,513,344  $2,051  $186,360  $(1,819) $(46,701) $(21,469) $124  $118,546 
                 

Balance June 30, 2022

 20,567,460  $2,057  $186,999  $(3,151) $(47,488) $(21,480) $130  $117,067 

Net loss

          (239)    (3) (242)

Stock option exercises

 750  -  3       -     3 

Stock-based compensation – stock options

      176           176 

Stock-based compensation -restricted stock

      3           3 

Vesting of restricted stock

 -  -  -       -     - 

Foreign currency translation adjustments

            (1,691)            (1,691)

Balance September 30, 2022

  20,568,210  $2,057  $187,181  $(4,842) $(47,727) $(21,480) $127  $115,316 

Balance June 30, 2023

  20,586,045  $2,059  $187,758  $(3,846) $(44,957) $(21,484) $145  $119,675 

 

The accompanying notes are an integral part of these consolidated financial statements.

 


 

ULTRALIFE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands except share and per share amounts)

(Unaudited)

 

 

1.

BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2021.2022.

 

The December 31, 20212022 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

 

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

 

Significant Accounting Policies

 

We regularly review of our accounting policiesDuring the quarter ended June 30, 2023, in consultation with third party experts, the Company completed an analysis to determine and make modifications as necessary to align with new accounting standards and changing business conditions.  Accordingly,verify its eligibility for the accounting policies below have been updated during the current year.  Reference should be made to Note 1 to the consolidated financial statements in our 2021 Annual Report on Form 10-K for all otherEmployee Retention Credit (“ERC”), which is a refundable tax credit against certain employment taxes under Section 2301 of the Company’s significant accounting policies.

Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”) and the American Rescue Plan of 2021, and filed the necessary amended payroll tax forms with the Internal Revenue Recognition:

Revenues are generated fromService to claim a refund for the salecredit.  The ERC refund receivable of products.  Performance obligations are met and revenue$1,544 is recognized upon transfer of control to the customer, which is generally upon shipment.  When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery.  For products shipped under vendor managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company.  Revenue is measured as the amount of consideration we expect to receiveincluded in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue.  Customers, including distributors, do not have a general right of return. 

Separately priced extended warranty contracts are offered on certain products.  Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract.  Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet.

For customer contracts with an original expected duration of less than one year, we apply the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

Warranties:

We generally offer standard warranties against product defects.  We also offer separately priced extended warranty contracts on certain products.  Warranty costs expected to be incurred are estimated based on the Company’s experience and recorded as costs of products sold.  Standard warranty costs are recognized upon product sale.  Extended warranty costs are recognized over the term of the contract.  Provision for warranty costs is recorded in accruedprepaid expenses and other current liabilities and other noncurrent liabilitiesassets on our consolidated balance sheet basedas of June 30, 2023, and the benefit is recognized as other income (expense) on our consolidated statement of income for the duration of the warranty.three and six-month periods ended June 30, 2023.

5

 

RecentRecently Adopted Accounting Guidance Not Yet Adopted

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments”, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company is currently assessing the impact that adoptingadoption of this new accounting standard willdid not have a material impact on our consolidated financial statements.

 

 

2.

ACQUISITION

On December 13, 2021, the Company acquired all the outstanding shares of Excell (as defined below) for an aggregate net purchase price of $23,519 in cash.

On December 13, 2021, 1336889 B.C. Unlimited Liability Company, a British Columbia unlimited liability company and wholly-owned subsidiary of Ultralife Canada Holding Corp., a Delaware corporation (“UCHC”) and wholly-owned subsidiary of Ultralife Excell Holding Corp., a Delaware corporation (“UEHC”) and wholly-owned subsidiary of Ultralife Corporation, completed the acquisition of all issued and outstanding shares of Excell Battery Canada Inc., a British Columbia corporation (“Excell Canada”) (the “Excell Canada Acquisition”), and, concurrently, 1336902 B.C. Unlimited Liability Company, a British Columbia unlimited liability company and wholly-owned subsidiary of UCHC, completed the acquisition of all issued and outstanding shares of 656700 B.C. LTD, a British Columbia corporation and sole owner of all issued and outstanding shares of Excell Battery Corporation USA, a Texas corporation (“Excell USA”, and together with Excell Canada, “Excell Battery Group” or “Excell”) (the “Excell USA Acquisition”, and together with the Excell Canada Acquisition, the “Excell Acquisition”).

Based in Canada with U.S. operations, Excell is a leading independent designer and manufacturer of high-performance smart battery systems, battery packs and monitoring systems to customer specifications. Excell serves a variety of industrial markets including downhole drilling, OEM industrial and medical devices, automated meter reading, ruggedized computers, and mining, marine and other mission critical applications which demand uncompromised safety, service, reliability and quality.

6

The Excell Canada Acquisition was completed pursuant to a Share Purchase Agreement dated December 13, 2021 (the “Excell Canada Acquisition Agreement”) by and among 1336889 B.C. Unlimited Liability Company, Mark Kroeker, Randolph Peters, Brian Larsen, M. & W. Holdings Ltd., Karen Kroeker, Heather Peterson, Michael Kroeker, Nicholas Kroeker, Brentley Peters, Craig Peters, Kurtis Peters, Heather Larsen, Ian Kane, Carol Peters, and 0835205 B.C. LTD (the “Excell Canada Sellers”), Mark Kroeker in his capacity as the Excell Canada Sellers’ Representative, and Excell Canada. The Excell USA Acquisition was completed pursuant to a Share Purchase Agreement dated December 13, 2021 (the “Excell USA Acquisition Agreement”, and together with the Excell Canada Acquisition Agreement, the “Excell Acquisition Agreements”) by and among 1336902 B.C. Unlimited Liability Company, M. & W. Holdings Ltd., Ian Kane, Sanford Capital Ltd., Arcee Enterprises Inc., and 0835205 B.C. Ltd. (the “Excell USA Sellers”, and together with the Excell Canada Sellers, the “Sellers”), Mark Kroeker in his capacity as the Excell USA Sellers’ Representative, and 656700 B.C. LTD. The Excell Acquisition Agreements contain customary terms and conditions including representations, warranties and indemnification provisions. A portion of the consideration paid to the Sellers is being held in escrow for indemnification purposes for a period of twelve months from the closing date.

The Excell Acquisition was funded by the Company through a combination of cash on hand and borrowings under the Amended Credit Facilities (Note 3).

The Excell Acquisition was accounted for in accordance with the accounting treatment of a business combination pursuant to FASB ASC Topic 805, Business Combinations (“ASC 805”). Accordingly, the purchase price was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values on the acquisition date. The excess of the purchase price over the estimated fair value of the separately identifiable assets acquired and liabilities assumed was allocated to goodwill. Management is responsible for determining the acquisition date fair value of the assets acquired and liabilities assumed, which requires the use of various assumptions and judgments that are inherently subjective. The purchase price allocation presented below reflects all known information about the fair value of the assets acquired and liabilities assumed as of the acquisition date. The purchase price allocation is subject to change should additional information existing as of the acquisition date about the fair value of the assets acquired and liabilities assumed becomes known. The final purchase price allocation may reflect material changes in the valuation of assets acquired and liabilities assumed, including but not limited to intangible assets, fixed assets, deferred taxes, and residual goodwill.

Cash

 $736 

Accounts receivable

  3,570 

Inventories

  3,622 

Prepaid expenses and other current assets

  785 

Property, plant and equipment

  429 

Goodwill

  10,989 

Other intangible assets

  8,870 

Other noncurrent assets

  991 

Accounts payable

  (1,450)

Accrued compensation and related benefits

  (540)

Accrued expenses and other current liabilities

  (720)

Deferred tax liability, net

  (2,223)

Other noncurrent liabilities

  (803)

Net assets acquired

 $24,256 

The purchase price allocation was adjusted during the nine-month period ended September 30, 2022 to reflect a change in the estimated fair value of certain other intangible assets acquired. The measurement period adjustment resulted in a $40 increase in other intangible assets acquired, a $10 increase in deferred tax liabilities and a $30 decrease to goodwill. The adjusted purchase price allocation is reflected in the consolidated balance sheet as of September 30, 2022.

The goodwill included in the Company’s purchase price allocation presented above represents the value of Excell’s assembled and trained workforce, the incremental value that Excell engineering and technology is expected to bring to the Company and the revenue growth expected to occur over time attributable to increased market penetration from future new products and customers. The goodwill acquired in connection with the acquisition is not deductible for income tax purposes.

Other intangible assets were valued using the income approach which requires a forecast of all expected future cash flows and the use of certain assumptions and estimates. The following table summarizes the estimated fair value and annual amortization for each of the identifiable intangible assets acquired.


          

Annual Amortization

 
  

Estimated
Fair Value

  

Amortization
Period (Years)

  

Year
1

  

Year
2

  

Year
3

  

Year
4

  

Year
5

 

Customer relationships

 $4,100   15  $273  $273  $273  $273  $273 

Trade name

  3,150  

Indefinite

   -   -   -   -   - 

Customer contracts

  1,140   15   76   76   76   76   76 

Backlog

  360   1   360   -   -   -   - 

Technology

  120   7   17   17   17   17   17 

Total

 $8,870      $726  $366  $366  $366  $366 

We acquired right-of-use assets and assumed lease liabilities of $960 for Excell’s operating facilities. Right-of-use assets are classified as other noncurrent assets, and current and long-term lease liabilities are classified as accrued expenses and other current liabilities and other noncurrent liabilities, respectively, on the Company’s consolidated balance sheet.

The operating results and cash flows of Excell are reflected in the Company’s consolidated financial statements from the date of acquisition. Excell is included in the Battery & Energy Products segment.

For the three months ended September 30, 2022, Excell contributed revenue of $6,871 and net income of $398, inclusive of amortization expense of $181 on acquired identifiable intangible assets. For the nine months ended September 30, 2022, Excell contributed revenue of $19,898 and net income of $1,112, inclusive of amortization expense of $545 on acquired identifiable intangible assets and $55 in cost of products sold attributable to the fair market value step-up of acquired inventory sold during the period.

3.

DEBT

 

On December 13, 2021, Ultralife, Southwest Electronic Energy Corporation, a Texas corporation and wholly owned subsidiary of Ultralife (“SWE”), CLB, INC., a Texas corporation and wholly owned subsidiary of SWE (“CLB”), Ultralife Excell Holding Corp., a Delaware corporation and wholly owned subsidiary of Ultralife (“UEHC”), Ultralife Canada Holding Corp., a Delaware corporation and wholly owned subsidiary of UEHC UCHC(“UCHC”), and Excell Battery Corporation USA, a Texas corporation and wholly owned subsidiary of UEHC (“Excell USA”), as borrowers, entered into the Second Amendment Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent, to amend the Credit and Security Agreement dated May 31, 2017 as amended by the First Amendment Agreement by and among Ultralife, SWE, CLB and KeyBank dated May 1, 2019 (the “Credit Agreement”). On November 28, 2022, Ultralife, SWE, CLB, UEHC, UCHC, Excell USA, and Excell Battery Canada ULC, a British Columbia unlimited liability corporation and wholly owned subsidiary of UCHC (“Excell Canada”), entered into that certain Third Amendment Agreement with KeyBank, to further amend the Credit Agreement to, among other things, facilitate the joinder of Excell Canada as a guarantor under the Credit Agreement and to replace the LIBOR benchmark thereunder with SOFR (the “Third Amendment Agreement”, and together with the Second Amendment Agreement and the Credit Agreement, the “Amended Credit Agreement”).


 

The Amended Credit Agreement, among other things, provides for a 5-year, $10,000 senior secured term loan (the “Term Loan Facility”) and extends the term of the $30,000 senior secured revolving credit facility (the “Revolving Credit Facility”, and together with the Term Loan Facility, the “Amended Credit Facilities”) through May 30, 2025. Up to six months prior to May 30, 2025, the Revolving Credit Facility may be increased to $50,000 with the Bank’s concurrence.

 

As of SeptemberJune 30, 2022,2023, the Company had $8,667$7,167 outstanding principal on the Term Loan Facility, $2,000 of which is included in current portion of long-term debt on the consolidated balance sheet, and $14,330$17,630 outstanding on the Revolving Credit Facility. As of SeptemberJune 30, 2022,2023, total unamortized debt issuance costs of $123,$155, including placement, renewal and legal fees associated with the Amended Credit Agreement, are classified as a reduction of long-term debt on the balance sheet. Debt issuance costs are amortized to interest expense over the term of the Amended Credit Facilities.

 

The remaining availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories.

 

The Company is required to repay the borrowings under the Term Loan Facility in equal consecutive monthly payments commencing on February 1, 2022, in arrears, together with applicable interest. All unpaid principal and accrued and unpaid interest with respect to the Term Loan Facility is due and payable in full on January 1, 2027. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on May 30, 2025. The Company may voluntarily prepay principal amounts outstanding at any time subject to certain restrictions.

 

8

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated senior leverage ratio,Consolidated Senior Leverage Ratio, as defined in the Amended Credit Agreement, of equal to or less than 3.5 to 1.0 for the fiscal quarters ending December 31, 2022 and March 31, 2023, and equal to or less than 3.0 to 1.0 for the fiscal quarters ending June 30, 2023 and thereafter. The Company was in full compliance with its covenants under the Amended Credit Agreement as of June 30, 2023.

 

Borrowings under the Amended Credit Facilities are secured by substantially all the assets of the Company and its subsidiaries.

 

Interest will accrueUpon the effectiveness of the Third Amendment Agreement, interest accrues on outstanding indebtedness under the Amended Credit Facilities at the BaseDaily Simple SOFR Rate, or the Overnight LIBOR Rate, as selected by the Company,plus an index spread adjustment of 0.10%, plus the applicable margin. The Base Rate is the highest of (a) the Prime Rate, (b) the Federal Funds Effective Rate plus 50 basis points, and (c) the Overnight LIBOR Rate plus one hundred basis points. The applicable margin ranges from zero to negative 50 basis points for the Base Rate and from 185 to 215 basis points for the Overnight LIBOR Rate and areis determined based on the Company’s senior leverage ratio. The Second Amendment Agreement includes standard market provisions permitting the Bank to transition from LIBOR to a SOFR based rate, in its discretion.

 

The Company must pay a fee of 0.15% to 0.25% based on the average daily unused availability under the Revolving Credit Facility.

 

Payments must be made by the Company to the extent borrowings exceed the maximum amount then permitted to be drawn on the Amended Credit Facilities and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

 


 

4.3.

EARNINGS PER SHARE

 

Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities, if any, and is calculated using the treasury stock method.

 

For the three-month period ended SeptemberJune 30, 2022,2023, there were no outstanding stock awards included in the calculation of diluted weighted average shares outstanding and no potential common shares included in the calculation of diluted EPS, as no securities were dilutive. There were 1,202,0764,166 outstanding stock options and 5,000 restricted stock awards not included in the calculation of diluted EPS for the three-month period ended September 30, 2022, as the effect would be antidilutive.

For the comparable three-month period ended September 30, 2021, there were no outstanding stock awards included in the calculation of diluted weighted average shares outstanding and no potential common shares included in the calculation of diluted EPS, as no securities were dilutive. There were 1,064,656 outstanding stock options and 14,164 restricted stock awards not included in the calculation of diluted EPS for the three-month period ended September 30, 2021, as the effect would be antidilutive.

For the nine-month period ended September 30, 2022, there were 128,665 outstanding stock options and 5,000 outstanding2,500 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 22,2032,334 potential common shares included in the calculation of diluted EPS. For the comparable nine-monththree-month period ended SeptemberJune 30, 2021, there were 598,4892022, 135,163 outstanding stock options and 14,164unvested 5,000 restricted stock awards were included in the calculation of diluted EPS, resulting in 20,352 potential common shares included in the calculation of diluted EPS. There were 1,289,862 and 1,073,077 outstanding stock options for the three-month periods ended June 30, 2023 and 2022, respectively, not included in EPS as the effect would be anti-dilutive.

For the six-month period ended June 30, 2023, there were no outstanding stock options and 2,500 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 179,9512,157 potential common shares included in the calculation of diluted EPS. For the comparable six-month period ended June 30, 2022, 135,163 outstanding stock options and 5,000 unvested restricted stock awards were included in the calculation of diluted EPS, resulting in 24,751 potential common shares included in the calculation of diluted EPS. There were 1,073,4111,294,028 and 466,1671,073,077 outstanding stock options for the six-month periods ended June 30, 2023 and 2022, respectively, not included in the calculation of diluted weighted average shares outstanding for the nine-month periods ended September 30, 2022 and September 30, 2021, respectively,EPS as the effect would be antidilutive.anti-dilutive.

9

 

 

5.4.

SUPPLEMENTAL BALANCE SHEET INFORMATION

 

Fair Value Measurements and Disclosures

 

The fair value of financial instruments approximated their carrying values at SeptemberJune 30, 20222023 and December 31, 2021.2022. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments.

 

Cash

 

The composition of the Company’s cash was as follows:

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Cash

 $4,978  $8,329  $8,202  $5,634 

Restricted cash

  73   84   81   79 

Total

 $5,051  $8,413  $8,283  $5,713 

 

As of SeptemberJune 30, 20222023 and December 31, 2021,2022, restricted cash included $73and $84,$81 and $79, respectively, of euro-denominated deposits withheld by the Dutch tax authorities and third-party VAT representatives in connection with a previously utilized logistics arrangement in the Netherlands. Restricted cash is included as a component of the cash balance for purposes of the consolidated statements of cash flows.

 

Inventories, Net

 

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

 

  

June 30,

  

December 31,

 
  

2023

  

2022

 

Raw materials

 $32,496  $29,200 

Work in process

  4,125   2,757 

Finished goods

  9,442   9,235 

Total

 $46,063  $41,192 

 

  

September 30,

  

December 31,

 
  

2022

  

2021

 

Raw materials

 $28,485  $21,660 

Work in process

  3,215   4,227 

Finished goods

  9,069   7,302 

Total

 $40,769  $33,189 
7

 

Property, Plant and Equipment, Net

 

Major classes of property, plant and equipment consisted of the following:

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Land

 $1,273  $1,273  $1,273  $1,273 

Buildings and leasehold improvements

 15,483  15,442  15,569  15,572 

Machinery and equipment

 63,724  63,780  64,044  63,981 

Furniture and fixtures

 2,787  2,588  2,791  2,845 

Computer hardware and software

 7,589  7,579  7,798  7,744 

Construction in process

  1,041   761   1,847   1,245 
 91,897  91,423  93,322  92,660 

Less: Accumulated depreciation

  (69,999)  (68,218)  (72,200)  (70,944)

Property, plant and equipment, net

 $21,898  $23,205  $21,122  $21,716 

 

Depreciation expense for property, plant and equipment was as follows:

 

  

Three-month period ended

  

Nine-month period ended

 
  

September 30,

  

September 30,

  

September 30,

  

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Depreciation expense

 $815  $700  $2,450  $2,160 
  Three-month period ended  

Six-month period ended

 
  

June 30,

  

June 30,

  

June 30,

  

June 30,

 
  

2023

  

2022

  

2023

  

2022

 

Depreciation expense

 $760  $819  $1,522  $1,635 

 


 

Goodwill

 

The following table summarizes the goodwill activity by segment for the nine-monthsix-month period ended SeptemberJune 30, 2022.2023.

 

  

Battery &

Energy

  

Communications

     
  

Products

  

Systems

  

Total

 

Balance – December 31, 2021

 $26,575  $11,493  $38,068 

Measurement period adjustment (1)

  (30)  -   (30)

Effect of foreign currency translation

  (972)  -   (972)

Balance – September 30, 2022

 $25,573  $11,493  $37,066 
  Battery &

Energy

  

Communications

     
  

Products

  

Systems

  

Total

 

Balance – December 31, 2022

 $25,935  $11,493  $37,428 

Effect of foreign currency translation

  73   -   73 

Balance – June 30, 2023

 $26,008  $11,493  $37,501 

 

(1)

Change for measurement period adjustment related to Excell Acquisition (Note 2).

 

Other Intangible Assets, Net

 

The composition of other intangible assets was:

 

 

at September 30, 2022

  

at June 30, 2023

 
     

Accumulated

         

Accumulated

    
 

Cost

  

Amortization

  

Net

  

Cost

  

Amortization

  

Net

 

Customer relationships

 $12,781  $5,757  $7,024  $13,079  $6,346  $6,733 

Patents and technology

 5,481  5,092  389  5,600  5,259  341 

Trade names

 4,601  475  4,126  4,645  589  4,056 

Trademarks

 3,401  -  3,401  3,399  -  3,399 

Other

  1,500   345   1,155   1,500   477   1,023 

Total other intangible assets

 $27,764  $11,669  $16,095  $28,223  $12,671  $15,552 

 

  

at December 31, 2021

 
      

Accumulated

     
  

Cost

  

Amortization

  

Net

 

Customer relationships

 $13,214  $5,484  $7,730 

Patents and technology

  5,667   5,126   541 

Trade names

  4,670   436   4,234 

Trademarks

  3,413   -   3,413 

Other

  1,490   18   1,472 

Total other intangible assets

 $28,454  $11,064  $17,390 

  

at December 31, 2022

 
      

Accumulated

     
  

Cost

  

Amortization

  

Net

 

Customer relationships

 $12,970  $5,992  $6,978 

Patents and technology

  5,557   5,171   386 

Trade names

  4,629   522   4,107 

Trademarks

  3,404   -   3,404 

Other

  1,500   454   1,046 

Total other intangible assets

 $28,060  $12,139  $15,921 

 

The change in the cost of total intangible assets from December 31, 20212022 to SeptemberJune 30, 20222023 is a result of measurement period adjustments for the Excell Acquisition (Note 2) and the effect of foreign currency translations.

 

Amortization expense for other intangible assets was as follows:

 

 

Three-month period ended

  

Nine-month period ended

  

Three-month period ended

  

Six-month period ended

 
 

September 30,

 

September 30,

 

September 30,

 

September 30,

  

June 30,

 

June 30,

 

June 30,

 

June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 
Amortization included in:                  

Selling, general and administrative

 $203  $298  $388  $600 

Research and development

 $23  $27  $74  $93   24   25   48   51 

Selling, general and administrative

  295   121   895   365 

Total amortization expense

 $318  $148  $969  $458  $227  $323  $436  $651 

 


 

 

6.5.

STOCK-BASED COMPENSATION

 

We recorded non-cash stock compensation expense in each period as follows:

 

 

Three-month period ended

  

Nine-month period ended

  

Three-month period ended

  

Six-month period ended

 
 

September 30,

 

September 30,

 

September 30,

 

September 30,

  

June 30,

 

June 30,

 

June 30,

 

June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Stock options

 $176  $131  $538  $468  $153  $181  $291  $362 

Restricted stock grants

  3   11   14   44 

Restricted stock

  1   3   2   11 

Total

 $179  $142  $552  $512  $154  $184  $293  $373 

 

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of SeptemberJune 30, 2022,2023, there was $393$438 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 1.01.1 years.


 

The following table summarizes stock option activity for the nine-monthsix-month period ended SeptemberJune 30, 2022:2023:

 

  

Number of
Shares

  

Weighted
Average
Exercise
Price

  

Weighted
Average
Remaining
Contractual
Term (years)

  

Aggregate
Intrinsic
Value

 

Outstanding at January 1, 2022

  1,306,824  $6.87         

Granted

  11,500   4.49         

Exercised

  (59,500)  3.82         

Forfeited or expired

  (56,748)  6.63         

Outstanding at September 30, 2022

  1,202,076  $7.01   3.81  $70 

Vested and expected to vest at September 30, 2022

  1,119,892  $7.04   3.67  $70 

Exercisable at September 30, 2022

  803,774  $7.22   2.82  $67 
  

Number of

Shares

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Term (years)

  

Aggregate

Intrinsic

Value

 

Outstanding at January 1, 2023

  1,425,693  $6.72         

Granted

  12,500  $4.07         

Exercised

  (44,390) $4.29         

Forfeited or expired

  (99,775) $4.84         

Outstanding at June 30, 2023

  1,294,028  $6.93   3.66  $15,640 

Vested and expected to vest at June 30, 2023

  1,188,048  $7.01   3.52  $13,124 

Exercisable at June 30, 2023

  858,695  $7.44   2.45  $2,304 

 

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended SeptemberJune 30, 2023 and June 30, 2022 was $62 and September 30, 2021 was $3 and $84,$0, respectively. Cash received from stock option exercises under our stock-based compensation plans for the nine-monthsix-month periods ended SeptemberJune 30, 2023 and June 30, 2022 was $62 and September 30, 2021 was $116 and $398,$113, respectively.

 

Outstanding restricted shares vest in equal annual installments over three(3) (3) years. There were 5,000 unvested restricted shares outstanding as of September 30, 2022. Unrecognized compensation cost related to theseoutstanding restricted shares at June 30, 2023 was $4 at September 30, 2022, which is expected to be recognized over a weighted average period of 1.1 years.$1.

 


 

 

7.6.

INCOME TAXES

 

Our effective tax rate for the nine-monthsix-month periods ended SeptemberJune 30, 2023 and June 30, 2022 was 29.2% and September 30, 2021 was 259.1% and 24.4%(30.5%), respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results and the larger effectimpact of permanent and discrete adjustments in the currentprior year.

 

As of December 31, 2021,2022, we have domestic net operating loss (“NOL”) carryforwards of $44,716,$40,952, which expire 2022 thru 2037,2025 through 2035, and domestic tax credits of $2,239,$2,600, which expire 2028 thru 2039,through 2042, available to reduce future taxable income. As of SeptemberJune 30, 2022,2023, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

 

As of SeptemberJune 30, 2022,2023, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $10,000, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

 

As of SeptemberJune 30, 2022,2023, we have not recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

 

As of SeptemberJune 30, 2022,2023, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

 

There were no unrecognized tax benefits related to uncertain tax positions at SeptemberJune 30, 20222023 and December 31, 2021.2022.

 

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. In August 2020, the Internal Revenue Service (“IRS”) completed its examination of the Company’s federal tax returns for 2016-2018 with no material adjustments identified.  Our U.S. tax matters for 2019-20212019-2022 remain subject to IRS examination. Our U.S. tax matters for 20022005, 2005-2007-2007 and 2011-2015 also remain subject to IRS examination due to the remaining availability of NOLnet operating loss carryforwards generated in those years. Our U.S. tax matters for 20022005, 2005-2007-2007 and 2011-20212011-2022 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 20112013 through 20212022 remain subject to examination by the respective foreign tax jurisdiction authorities.

 

10

 

8.7.

OPERATING LEASES

 

The Company has operating leases predominantly for operating facilities. As of SeptemberJune 30, 2022,2023, the remaining lease terms on our operating leases range from approximately one ((1)1) year to ten (10)eight (8) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

 

The components of lease expense for the current and prior-year comparative periods were as follows:

 

  

Three months ended

  

Nine months ended

 
  

September
30, 2022

  

September
30, 2021

  

September
30, 2022

  

September
30, 2021

 

Operating lease cost

 $216  $188  $674  $564 

Variable lease cost

  22   25   69   57 

Total lease cost

 $238  $213  $743  $621 


  

Three months ended

  

Six months ended

 
  

June 30,

2023

  

June 30,

2022

  

June 30,

2023

  

June 30,

2022

 

Operating lease cost

 $239  $226  $480  $458 

Variable lease cost

  29   23   57   47 

Total lease cost

 $268  $249  $537  $505 

 

Supplemental cash flow information related to leases was as follows:

 

 

Nine-month period ended

  

Six-month period ended June 30,

 
 

September
30, 2022

  

September
30, 2021

  

2023

  

2022

 
Cash paid for amounts included in the measurement of lease liabilities:  

Operating cash flows used in operating leases

 $676  $550 

Operating cash flows from operating leases

 $494  $449 

Right-of-use assets obtained in exchange for lease liabilities:

 $310  $- 

 

Supplemental consolidated balance sheet information related to leases was as follows:

 

Balance sheet classification

 

September
30, 2022

  

December
31, 2021

 

Balance sheet classification

 

June 30,

2023

  

December 31,

2022

 

Assets:

  

Operating lease right-of-use asset

Other noncurrent assets

 $1,861  $2,581 Other noncurrent assets $2,187  $2,187 
  

Liabilities:

  

Current operating lease liability

Accrued expenses and other current liabilities

 $824  $867 Accrued expenses and other current liabilities $968  $895 

Operating lease liability, net of current portion

Other noncurrent liabilities

  1,064   1,743 Other noncurrent liabilities  1,199   1,307 

Total operating lease liability

Total operating lease liability

 $1,888  $2,610 Total operating lease liability $2,167  $2,202 
  

Weighted-average remaining lease term (years)

Weighted-average remaining lease term (years)

 4.2  4.5 Weighted-average remaining lease term (years) 4.4  4.7 
  

Weighted-average discount rate

Weighted-average discount rate

 4.5% 4.5%Weighted-average discount rate 4.5% 4.5%

 

Future minimum lease payments as of SeptemberJune 30, 20222023 are as follows:

 

Maturity of operating lease liabilities

      

2022

 $212 

2023

 840  $520 

2024

 430  652 

2025

 128  313 
2026 129  245 
2027 129  222 
Thereafter 264  436 

Total lease payments

 2,132  2,388 

Less: Imputed interest

 (244) (221)

Present value of remaining lease payments

 $1,888  $2,167 

 


11

 

 

9.8.

COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of SeptemberJune 30, 2022,2023, we have made commitments to purchase approximately $624$1,023 of production machinery and equipment.

 

Product Warranties

 

We generally offer standard warranties against product defects.  We also offer separately priced extendedestimate future warranty contracts on certain products.  Warranty costs expected to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are estimated based on the Company’sactual past experience and recordedare generally estimated as costsa percentage of products sold.  Standard warranty costs are recognized upon product sale.  Extended warranty costs are recognizedsales over the termwarranty period. Changes in our product warranty liability during the first six months of the contract. 2023 and 2022 were as follows:

 

 

Nine-month period ended September 30,

  

Six-month period ended June 30,

 
 

2022

 

2021

  

2023

  

2022

 

Accrued warranty obligations – beginning

 $133  $149  $323  $133 

Accruals for warranties issued

 247  123  172  25 

Settlements made

  (94)  (143)  (62)  (26)

Accrued warranty obligations – ending

 $286  $129  $433  $132 

 

Contingencies and Legal Matters

 

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

 

 
10.9.

REVENUE RECOGNITION

 

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor managedvendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

 

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheet.

 

As of SeptemberJune 30, 2023, there was deferred revenue on extended warranty contracts of $944, comprised of $164 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheet, and $780 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

As of December 31, 2022, there was deferred revenue on extended warranty contracts of $592 in other noncurrent liabilities$682, comprised of $119 expected to be recognized as revenue within one (1) year and $119 inclassified as accrued expenses and other current liabilities on our consolidated balance sheet, and $563 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheet.

12

As of June 30, 2023 and December 31, 2021,2022, the Company had no extended warranty other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

 


 

 

11.10.

BUSINESS SEGMENT INFORMATION

 

We report our results in two (2) operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes:includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes:includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. We report operating expenses as Corporate charges.

 

Three-month period ended SeptemberJune 30, 2022:2023:

 

 

Battery &
Energy
Products

  

Communications

Systems

  

Corporate

  

Total

  

Battery &

Energy

Products

  

Communications

Systems

  

Corporate

  

Total

 

Revenues

 $28,583  $4,651  $-  $33,234  $33,861  $8,831  $-  $42,692 

Segment contribution

 5,345  1,370  (7,301) (586) 7,543  3,045  (6,923) 3,665 

Other income

      254  254       1,058  1,058 

Income tax benefit

      90  90 

Income tax provision

      (1,375) (1,375)

Non-controlling interest

      3  3       (8) (8)

Net loss attributable to Ultralife

        $(239)

Net income attributable to Ultralife

        $3,340 

Three-month period ended June 30, 2022:

  

Battery &

Energy

Products

  

Communications

Systems

  

Corporate

  

Total

 

Revenues

 $30,140  $1,986  $-  $32,126 

Segment contribution

  7,151   495   (6,853)  793 

Other expense

          (115)  (115)

Income tax provision

          (170)  (170)

Non-controlling interest

          4   4 

Net income attributable to Ultralife

             $512 

Six-month period ended June 30, 2023:

  

Battery &

Energy

Products

  

Communications

Systems

  

Corporate

  

Total

 

Revenues

 $62,331  $12,277  $-  $74,608 

Segment contribution

  14,055   3,969   (14,333)  3,691 

Other income

          564   564 

Income tax provision

          (1,242)  (1,242)

Non-controlling interest

          (19)  (19)

Net income attributable to Ultralife

             $2,994 

 


 

Three-monthSix-month period ended SeptemberJune 30, 2021:2022:

 

 

Battery &
Energy
Products

  

Communications

Systems

  

Corporate

  

Total

  

Battery &

Energy

Products

  

Communications

Systems

  

Corporate

  

Total

 

Revenues

 $20,008  $1,753  $-  $21,761  $59,290  $3,209  $-  $62,499 

Segment contribution

 4,792  316  (5,887) (779) 13,872  732  (14,106) 498 

Other income

      1  1 

Other expense

      (232) (232)

Income tax benefit

      175  175       81  81 

Non-controlling interest

      18  18       (3) (3)

Net loss attributable to Ultralife

        $(585)

Net income attributable to Ultralife

        $344 

 

Nine-month period ended September 30, 2022:

  

Battery &
Energy
Products

  

Communications
Systems

  

Corporate

  

Total

 

Revenues

 $87,873  $7,860  $-  $95,733 

Segment contribution

  19,217   2,102   (21,407)  (88)

Other income

          22   22 

Income tax benefit

          171   171 

Non-controlling interest

          -   - 

Net income attributable to Ultralife

             $105 

Nine-month period ended September 30, 2021:

  

Battery &
Energy
Products

  

Communications Systems

  

Corporate

  

Total

 

Revenues

 $64,994  $9,510  $-  $74,504 

Segment contribution

  16,244   3,109   (18,089)  1,264 

Other expense

          (76)  (76)

Income tax provision

          (290)  (290)

Non-controlling interest

          (1)  (1)

Net income attributable to Ultralife

             $897 


 

The following tables disaggregate our business segment revenues by major source and geography.

 

Commercial and Government/Defense Revenue Information:

 

Three-month period ended SeptemberJune 30, 2022:2023:

 

 

Total

Revenue

  

Commercial

  

Government/

Defense

  

Total

Revenue

  

Commercial

  

Government/

Defense

 

Battery & Energy Products

 $28,583  $22,878  $5,705  $33,861  $26,950  $6,911 

Communications Systems

  4,651   -   4,651   8,831   -   8,831 

Total

 $33,234  $22,878  $10,356  $42,692  $26,950  $15,742 
      69%  31%      63%  37%

 

Three-month period ended September 30, 2021:

  

Total

Revenue

  

Commercial

  

Government/

Defense

 

Battery & Energy Products

 $20,008  $16,579  $3,429 

Communications Systems

  1,753   -   1,753 

Total

 $21,761  $16,579  $5,182 
       76%  24%

Nine-month period ended SeptemberJune 30, 2022:

 

 

Total

Revenue

  

Commercial

  

Government/

Defense

  

Total

Revenue

  

Commercial

  

Government/

Defense

 

Battery & Energy Products

 $87,873  $70,154  $17,719  $30,140  $24,682  $5,458 

Communications Systems

  7,860   -   7,860   1,986   -   1,986 

Total

 $95,733  $70,154  $25,579  $32,126  $24,682  $7,444 
      73%  27%      77%  23%

 

Nine-monthSix-month period ended SeptemberJune 30, 2021:2023:

 

 

Total

Revenue

  

Commercial

  

Government/

Defense

  

Total

Revenue

  

Commercial

  

Government/

Defense

 

Battery & Energy Products

 $64,994  $46,935  $18,059  $62,331  $49,169  $13,162 

Communications Systems

  9,510   -   9,510   12,277   -   12,277 

Total

 $74,504  $46,935  $27,569  $74,608  $49,169  $25,439 
      63%  37%      66%  34%

Six-month period ended June 30, 2022:

  

Total

Revenue

  

Commercial

  

Government/

Defense

 

Battery & Energy Products

 $59,290  $47,276  $12,014 

Communications Systems

  3,209   -   3,209 

Total

 $62,499  $47,276  $15,223 
       76%  24%

 


 

U.S. and Non-U.S. Revenue Information1:

 

Three-month period ended SeptemberJune 30, 2022:2023:

 

 

Total

Revenue

  

United
States

  

Non-United
States

  

Total

Revenue

  

United

States

  

Non-United

States

 

Battery & Energy Products

 $28,583  $13,433  $15,150  $33,861  $17,394  $16,467 

Communications Systems

  4,651   3,547   1,104   8,831   3,945   4,886 

Total

 $33,234  $16,980  $16,254  $42,692  $21,339  $21,353 
      51%  49%      50%  50%

 

Three-month period ended September 30, 2021:

  

Total

Revenue

  

United
States

  

Non-United
States

 

Battery & Energy Products

 $20,008  $7,941  $12,067 

Communications Systems

  1,753   1,249   504 

Total

 $21,761  $9,190  $12,571 
       42%  58%

Nine-month period ended SeptemberJune 30, 2022:

 

 

Total

Revenue

  

United
States

  

Non-United
States

  

Total

Revenue

  

United

States

  

Non-United

States

 

Battery & Energy Products

 $87,873  $41,303  $46,570  $30,140  $13,330  $16,810 

Communications Systems

  7,860   6,609   1,251   1,986   1,910   76 

Total

 $95,733  $47,912  $47,821  $32,126   15,240  $16,886 
      50%  50%      47%  53%

 

Nine-monthSix-month period ended SeptemberJune 30, 2021:2023:

 

 

Total

Revenue

  

United
States

  

Non-United
States

  

Total

Revenue

  

United

States

  

Non-United

States

 

Battery & Energy Products

 $64,994  $32,344  $32,650  $62,331  $31,162  $31,169 

Communications Systems

  9,510   4,670   4,840   12,277   6,822   5,455 

Total

 $74,504  $37,014  $37,490  $74,608  $37,984  $36,624 
      50%  50%      51%  49%

Six-month period ended June 30, 2022:

  

Total

Revenue

  

United

States

  

Non-United

States

 

Battery & Energy Products

 $59,290  $27,870  $31,420 

Communications Systems

  3,209   3,062   147 

Total

 $62,499  $30,932  $31,567 
       49%  51%

 

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

 


 

 

Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements and information that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, changes in economic conditions including inflation and supply chain disruptions affecting our business, revenues and earnings adversely; the continued impact of COVID-19 causing delays in the manufacture and the related supply chain disruptions ondelivery of our business, operating results and financial condition;mission critical products to end customers;  our reliance on certain key customers; our efforts to develop new commercial applications for our products; reduced U.S. and foreign military spending including the uncertainty associated with government budget approvals; the unique risks associated with our efforts to develop new commercial applications forChina operations; breaches in information systems security and other disruptions in our products;information technology systems; potential disruptions in our supply of raw materials and components; fluctuations in the price of oil and the resulting impact on the demand for downhole drilling; the unique risks associated with our China operations; potential disruptions in our supply of raw materials and components; our ability to retain top management and key personnel; possible breaches in information systems security and other disruptions in our information technology systems; our resources being overwhelmed by our growth; possible future declines in demand for the products that use our batteries or communications systems; potential costs attributable to the warranties we supply with our products and services; safety risks, related to the nature of our products, including the risk of fire; variability in our quarterly and annual results and the price of our common stock; rising interest rates increasing the cost of our entrance into new end-markets which could leadvariable borrowings; purchases by our customers of product quantities not meeting the volume expectations in our supply agreements; potential costs attributable to additional financial exposure;the warranties we supply with our products and services; our inability to comply with changes to the regulations for the shipment of our products; our customers’ demand falling short of volume expectations inability to utilize our supply agreements;net operating loss carryforwards; our exposureentrance into new end-markets which could lead to foreign currency fluctuations;additional financial exposure; negative publicity concerning Lithium-ion batteries; possible impairments of our goodwill and other intangible assets; our abilityexposure to utilize our net operating loss carryforwards;foreign currency fluctuations; the risk that we are unable to protect our proprietary and intellectual property; rules and procedures regarding contracting with the U.S. and foreign governments; exposure to possible violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act or other anti-corruption laws; known and unknown environmental matters; possible audits of our contracts by the U.S. and foreign governments and their respective defense agencies; our ability to comply with government regulations regarding the use of “conflict minerals”; technological innovations by our competitors in the non-rechargeable and rechargeable battery industries; and other risks and uncertainties, certain of which are beyond our control.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements described herein. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “seek,” “project,” “intend,” “plan,” “may,” “will,” “should,” “would,” “could,” or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.2022.

 

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industries in which we operate may differ materially from those made in or suggested by the forward-looking statements contained herein. In addition, even if our results of operations, financial condition and liquidity and the development of the industries in which we operate are consistent with the forward-looking statements contained in this quarterly report, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

 

Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any risk factors or to publicly announce the results of any revisions to any of the forward-lookingforward looking statements contained in this Form 10-Q or our Annual Report on Form 10-K for the year ended December 31, 2021report to reflect new information or risks, future events or other developments.

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the consolidated financial statements and notes thereto in Part I, Item 1 of this Form 10-Q, and the consolidated financial statements and notes thereto and risk factors in our Annual Report on Form 10-K for the year ended December 31, 2021.2022.

 

The financial information in this MD&A is presented in thousands of dollars, except for share and per share amounts, unless otherwise specified.

 

2016

 

General

 

We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including: rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, penetrationexpansion of our sales force to penetrate new markets and territories, by our sales force, as well as seeking opportunities to expand through acquisitions.

 

We sell our products worldwide through a variety of trade channels, including original equipment manufacturers (“OEMs”), industrial and defense supply distributors, and directly to U.S. and foreign defense departments. We enjoy strong name recognition in our markets under our Ultralife® Batteries, Lithium Power®, McDowell Research®, AMTITM, ABLETM, ACCUTRONICS™, ACCUPRO™, ENTELLION™, SWE Southwest Electronic Energy Group™, SWE DRILL-DATA™, SWE SEASAFE™, Excell Battery GroupGroup™ and Criterion Gauge brands. We have sales, operations and product development facilities in North America, Europe and Asia.

 

We report our results in two operating segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes:includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes:includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. We believe that reporting performance at the gross profit level is the best indicator of segment performance. As such, we report segment performance at the gross profit level and operating expenses as Corporate charges. Seecharges (See Note 1110 in the notes to the consolidated financial statements of this Form 10-Q for further information.statements.)

 

Our website address is www.ultralifecorporation.com. We make available free of charge via a hyperlink on our website (see Investor Relations link on the website) our annual reports on Form 10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports and statements as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). We will provide copies of these reports upon written request to the attention of Philip A. Fain, CFO, Treasurer and Secretary, Ultralife Corporation, 2000 Technology Parkway, Newark, New York, 14513. Our filings with the SEC are also available through the SEC website at www.sec.gov or at the SEC Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 or by calling 1-800-SEC-0330.

 

COVID-19

The COVID-19 pandemic has created significant economic disruption and uncertainty around the world.  The Company continues to closely monitor the developments surrounding COVID-19 and take actions to mitigate the business risks involved.  During this challenging time, we remain focused on ensuring the health and safety of our employees by following the protocols established by public health officials and on meeting the demand of our customers.  We have maintained normal business operations at all our facilities with the exception of the well-publicized shutdowns in China which impacted our Shenzhen facility in the first quarter of 2022.  The COVID-19 related supply chain disruptions including increased lead times on key components experienced within our business and by our customers, impacted our work schedules and timing of shipments.  The continuing impact of these conditions on our business is uncertain and will depend on many evolving factors which we continue to monitor but cannot predict, including the duration, severity and scope of the pandemic and its variants, the resulting actions taken by governments, businesses and individuals, and the flow-through impact on operations and supply chains.  Potential ramifications from COVID-19 that may continue to adversely impact our future business include limited availability and/or increased cost of raw materials and components used in our products, reduced demand and/or pricing for our products, inability of our customers to pay for our products or remain solvent, and reduced availability of our workforce. Prolonged adverse effects of COVID-19 on our business could result in the impairment of long-lived assets including goodwill and other intangible assets.  Further, we cannot predict all possible adverse effects the COVID-19 pandemic may cause. Consequently, there may be adverse effects in addition to those described above. We will continue to closely monitor the developments surrounding COVID-19 and take actions when possible to mitigate the business risks involved and the potential effects of COVID-19 on our business.


 

Overview

 

Consolidated revenues of $33,234$42,692 for the three-month period ended SeptemberJune 30, 2022,2023, increased by $11,473$10,566 or 52.7%32.9%, over $21,761$32,126 for the three-month period ended SeptemberJune 30, 2021,2022, reflecting the revenues of Excell Battery Group (“Excell”) acquired on December 13, 2021, and increased salesincreases in our government/defense oilsales of 111.5% and commercial sales of 9.2%.  Sales for our Battery & gas and industrial battery markets, partially offset by lower revenues for medical which was dueEnergy Products segment increased 12.3% from $30,140 in the second quarter of 2022 to delayed sales caused by component shortages. Government/defense revenues of $10,356 increased $5,174 or 99.8% over the 2021 period, and excluding Excell, commercial revenues of $16,007$33,861 for the second quarter ended September 30, 2022 decreased $572 or 3.5%of 2023, and sales for our Communications Systems segment increased 344.6% from the year-earlier period.  Including the operations of Excell, commercial revenues were $22,878.$1,986 to $8,831.

 

Gross profit was $6,715,$10,588, or 20.2%24.8% of revenue, for the three-month period ended SeptemberJune 30, 2022,2023, compared to $5,108,$7,646, or 23.5%23.8% of revenue, for the same quarter a year ago. The 330-basis100-basis point declineimprovement primarily reflects incremental costs in 2022 associated with supply chain disruptions including component cost inflation, manufacturing inefficiencies resultingresulted from prolonged lead timeshigher factory volume and logistics delays, and the transitioning of new products to high volume production.favorable product mix for our Communications Systems business.

 

Operating expenses increased to $7,301$6,923 for the three-month period ended SeptemberJune 30, 2022,2023, compared to $5,887$6,853 for the three-month period ended SeptemberJune 30, 2021.2022. The increase of $1,414$70 or 24.0%1.0% was primarily attributable to our acquisition of Excell which contributed operating expenses of $1,115.  Excluding Excell, operating expenses increased by $299 or 5.1% reflecting increasedslightly higher new product development costs, travel expenses and sales commissions, as well as inflationary cost increases.investments in the 2023 period. Operating expenses as a percentagerepresented 16.2% of sales decreased 500 basis points from 27.0%revenues compared to 21.3% of revenues for the third quarter of 2021 to 22.0% for the current quarter highlighting our continued control over discretionary spending and positive sales leverage. year-earlier period.

 

Operating lossincome for the three-month period ended SeptemberJune 30, 20222023 was $586,$3,665, or 8.6% of revenues, compared to a loss$793, or 2.5% of $779,revenues, for the year-earlier period. The decreaseincrease in the operating lossincome resulted from higher sales from both of our business segments, offsetthe 32.9% increase in large partrevenues leveraged by a reductionthe 100-basis point improvement in gross margin dueand the 510-basis point improvement in operating expenses to increased costs resulting from supply chain disruptions, including inflationary cost pressuresrevenues ratio.

17

Other income (expense) for the second quarter of 2023 includes an Employee Retention Credit of $1,544 under Section 2301 of the Coronavirus Aid, Relief and prolonged component lead times and logistical delays causing manufacturing inefficiencies.Economic Security Act which was filed with the Internal Revenue Service during the period.

 

Net loss attributableincome was $3,340 or $0.21 per share – basic and diluted on a GAAP basis, compared to Ultralife was $239,net income of $512 million or ($0.01)$0.03 per share – basic and diluted for the three-month period ended September 30, 2022, compared to net loss attributable to Ultralifesecond quarter of $585, or ($0.04) per share –2022.  Adjusted EPS was $0.29 - basic and diluted for the three-month period ended September 30, 2021.  The reductionsecond quarter of net loss resulted from higher revenues in2023, compared to $0.03 - basic and diluted for the 2022 quarter.period. Adjusted EPS excludes the provision for deferred taxes of $1,278 which primarily represents non-cash charges for U.S. taxes which will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. See the section “Adjusted EPS” on Page 23 for a reconciliation of adjusted EPS to EPS.

 

Adjusted EBITDA, defined as net income (loss) attributable to Ultralife before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expenses/income that we do not consider reflective of our ongoing operations, amounted to $1,255,$6,296, or 3.8%14.7% of revenues, for the thirdsecond quarter of 2022,2023, compared to $283,$2,185, or 1.3%6.8% of revenues, for the thirdsecond quarter of 2021.2022. See the section “Adjusted EBITDA” beginning on Page 2621 for a reconciliation of adjusted EBITDA to net income attributable to Ultralife.

 

With a backlog now over $100,000, we are positioned wellincreasing to $110,875 and durable demand across our diverse end markets, the near-term highest priority remains to recapture gross margin through continued execution of price realization activities, qualification of alternate component suppliers, and lean manufacturing initiatives.  These actions position us to deliver high-quality, sustainable profitable growth for near-term revenue increases2023 generating incremental cash flow to pay down our acquisition debt and remain committedfurther invest in our businesses.  We continue to advancing several transformational projects andstrengthen our relationships with our key customers using our global new product opportunitiesdevelopment and sales resources to drive long-term revenue growth.support future growth in target markets.

 

 

Results of Operations

 

Three-Month Periods Ended SeptemberJune 30, 20222023 and SeptemberJune 30, 20212022

 

Revenues. Consolidated revenues for the three-month period ended SeptemberJune 30, 20222023 were $33,234,$42,692, an increase of $11,473,$10,566, or 52.7%32.9%, over $21,761$32,126 for the three-month period ended SeptemberJune 30, 2021.2022. Overall, government/defense sales increased 99.8%, or $5,174,111.5% and commercial sales increased 38.0%, or $6,299, from the 2021 period.  Revenues for the 2022 period include the results of Excell which was acquired by the Company on December 13, 2021. Our revenue backlog, consisting of committed firm orders, was $106,200 at September 30, 2022, an increase of 34.1% over the backlog at June 30, 2022 and 154% over the backlog at September 30, 2021.9.2%.

 

Battery & Energy Products revenues increased $8,575,$3,721, or 42.9%12.3%, from $20,008$30,140 for the three-month period ended SeptemberJune 30, 20212022 to $28,583$33,861 for the three-month period ended SeptemberJune 30, 2022.2023, reflecting increases of $2,268 or 9.2% in commercial sales and $1,453 and 26.6% in government/defense sales.  The increase in commercial sales was attributable to the $6,870 revenue contribution from the acquisition of Excell, coupled withdriven by a 66.4%,$1,966 or $2,276,25.2% increase in government/defensemedical sales reflecting an increased demand for our batteries used in ventilators, respirators, infusion pumps and other medical devices and a 7.4%,$1,694 or $318,17.9% increase in oil & gas market sales andreflecting a 2.4%, or $116, increaserebound in industrial marketthe energy sector.  These increases in commercial sales were partially offset by a 12.1%,$1,392 or $904,18.8% decrease in medical sales.  Net sales for this segment, excluding the results of Excell, increased 8.5%, or $1,706.  The increase in government/defenseindustrial and other commercial sales primarily resulted from strong order flow from a large global defense prime contractor.  The increaseattributable to 9-Volt and our new Thionyl Chloride and thin cell battery cells for which sales are expected to rebound in oil & gas market sales was driven by higher demand for our battery packs for downhole drilling in both U.S. and international markets.  The decline in medical sales resulted from component shortages in the current quarter to fulfill the increased demand for our products.  The revenue backlog for this segment is now at its highest level in our Company’s history.future periods.

22

 

Communications Systems revenuessales increased $2,898,$6,845, or 165.3%344.6%, from $1,753$1,986 for the three-month period ended SeptemberJune 30, 20212022 to $4,651$8,831 for the three-month period ended SeptemberJune 30, 2022. This2023. The increase iswas primarily attributable to our receiptshipments of componentsvehicle-amplifier adaptor orders to commencea global defense contractor for the fulfillmentU.S. Army and of modest shipments under various large program awards.integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor for an ongoing allied country government/defense modernization program.

Our total backlog at June 30, 2023 was $110,875 representing a 40.1% increase over the comparable $79,147 for the same period last year, with $76,400 due to ship over the remaining six months of 2023.  Total backlog increased $2,772 or 2.6% compared to the backlog of $108,102 at March 31, 2023.

 

Cost of Products Sold / Gross Profit. Consolidated costCost of products sold totaled $26,519$32,104 for the quarter ended SeptemberJune 30, 2022,2023, an increase of $9,866,$7,624, or 59.2%31.1%, from the $16,653$24,480 reported for the same three-month period a year ago. Consolidated cost of products sold as a percentage of total revenue increaseddecreased from 76.5%76.2% for the three-month period ended SeptemberJune 30, 20212022 to 79.8%75.2% for the three-month period ended SeptemberJune 30, 2022.2023. Correspondingly, consolidated gross margin decreasedincreased from 23.5%23.8% for the three-month period ended SeptemberJune 30, 2021,2022, to 20.2%24.8% for the three-month period ended SeptemberJune 30, 2022,2023, primarily reflecting increased costs attributable to ongoing component cost inflation, manufacturing inefficiencies related to prolonged lead timeshigher factory volume and logistics delays, and the incremental costs of transitioning new products to higher volume production.favorable product mix for our Communications Systems business.

 

For our Battery & Energy Products segment, gross profit for the thirdsecond quarter of 20222023 was $5,345,$7,543, an increase of $553$392 or 11.5% over5.5% from gross profit of $4,792$7,151 for the thirdsecond quarter of 2021.2022. Battery & Energy Products’ gross margin of 18.7%22.3% decreased by 530 basis140-basis points from the 24.0%23.7% gross margin for the year-earlier period, primarily reflecting rapid cost inflation on components not fully aligned with customer price increases, manufacturinglingering inefficiencies associated with component availability, prolonged lead timesresulting from the January 2023 cyberattack, disposition of certain non-conforming materials and related logistics delays impacting timely deliveries, and incremental costs associated withcontinued investments in the transition of new products to higherhigh volume production.production, partially offset by improved price realization.

18

 

For our Communications Systems segment, gross profit for the thirdsecond quarter of 20222023 was $1,370$3,045 or 29.5%34.5% of revenues, compared to gross profit of $316$495 or 18.0%24.9% of revenues for the thirdsecond quarter of 2021.2022. The 960-basis point increase in gross margin was primarily due to higher factory volume and favorable sales mix.product mix compared to last year’s second quarter.

 

Operating Expenses.Expense. Consolidated operating expenses for the three-month period ended September 30, 2022 were $7,301, an increase of $1,414 or 24.0% from the $5,887 for the three-month period ended September 30, 2021.  The increase is primarily attributable to the acquisition of Excell, which contributed operating expenses of $1,115 in the third quarter, including $181 of intangible asset amortization.  Excluding Excell, operating expenses increased $299 or 5.1% due to increased new product development, travel, and sales commissions, as well as inflationary cost increases. Both periods reflected continued tight control over discretionary spending.

Overall, operating expenses as a percentagewere 16.2% of revenues were 22.0%revenue for the quarter ended SeptemberJune 30, 20222023 compared to 27.1%21.3% of revenue for the quarter ended SeptemberJune 30, 2021 resulting from sales leverage and control over discretionary spending.2022. Amortization expense associated with intangible assets related to our acquisitions was $318$227 for the thirdsecond quarter of 20222023 ($295203 in selling, general and administrative expenses and $23$24 in research and development costs), compared with $148$323 for the thirdsecond quarter of 20212022 ($121298 in selling, general, and administrative expenses and $27$25 in research and development costs). Research and development costs were $1,896$1,778 for the three-month period ended SeptemberJune 30, 2022,2023, an increase of $173$106 or 10.0%6.3%, from $1,723$1,672 for the three-months ended SeptemberJune 30, 2021.2022. The increase is largely attributable to the operations of Excell, acquiredan increase in December 2021, and increased investmentsnew product development in our Communications Systems business to develop new products expanding the business into selectpursue both government/defense major programs and commercial markets.opportunities. Selling, general, and administrative expenses increased $1,241 or 29.8%, to $5,405were essentially flat year over year, decreasing from $5,181 for the thirdsecond quarter of 2022 from $4,164to $5,145 for the thirdsecond quarter of 2021.2023.

Other Income (Expense). Other income (expense) totaled $1,058 for the three-month period ended June 30, 2023 compared to ($115) for the three-month period ended June 30, 2022.  Other income for the 2023 period includes an Employee Retention Credit (“ERC”) of $1,544 under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during the second quarter of 2023. Interest and financing expense increased $263, or 148.6%, from ($177) for the second quarter of 2022 to ($440) for the comparable period in 2023. The increase is mostly attributableprimarily due to the operationsfinancing of our acquisition of Excell which contributed $1,026 of selling, generalin December 2021, working capital funding resulting from the January 2023 cyberattack and administrative expenses, including intangible asset amortization of $181,rising interest rates. Excluding the $1,544 gain for the thirdERC, miscellaneous income (expense) amounted to ($46) for the second quarter of 2023 compared to $62 for the second quarter of 2022, with the remainder reflecting inflationary cost increases. primarily attributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange rates.

23

 

Income Taxes. ForThe tax provision for the three-month period ended September 30,2023 second quarter was $1,375 compared to $170 for the second quarter of 2022. Our effective tax rate increased to 29.1% for the second quarter of 2023 as compared to 25.1% for the second quarter of 2022, Ultralife recognized anprimarily attributable to the magnitude of our income reported in the 2023 quarter, including the Employee Retention Credit, and the geographic mix of our operating results.  The income tax benefitprovision for the second quarter of $90,2023 is comprised of a $218$97 current provision for taxes expected to be paid on income primarily from our non-U.S. operations,in foreign jurisdictions, representing a cash-based effective tax rate of 2.1%, and a $308$1,278 deferred benefit, compared to antax provision which primarily represents non-cash charges for U.S. taxes that will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  For the comparable 2022 period, the income tax benefit of $175 for the three-month period ended September 30, 2021,provision was comprised of a $43$143 current tax provision, andrepresenting a $218 deferred benefit. Ourcash-based effective tax rate was 27.1% forof 21.1%, and a $27 deferred tax provision. The period over period change in the third quarter of 2022 as compared to 22.5% for the third quarter of 2021,cash-based effective tax rate is primarily attributable to the geographic mix of our operating results, including income generated in Canada by Excell for the current year.results. See Note 76 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for further information.additional information regarding our income taxes.

 

Net LossIncome Attributable to Ultralife. Net lossincome attributable to Ultralife was $239,$3,340, or ($0.01)$0.21 per share – basic and diluted on a GAAP basis for the three-month period ended June 30, 2023, compared to $512, or $0.03 per share – basic and diluted, for the three-month period ended SeptemberJune 30, 2022,2022.  Adjusted EPS was $0.29 on a diluted basis for the second quarter of 2023, compared to net loss attributable to Ultralife of $585, or ($0.04) per share – basic and diluted,$0.03 for the three-month period ended September 30, 2021.  The reduction in net loss is primarily attributable to higher salessecond quarter of 2022.  Adjusted EPS excludes the provision for deferred taxes of $1,278 and $27 for the 2023 and 2022 quarter. periods, respectively, which primarily represent non-cash charges for U.S. taxes that will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  See the section “Adjusted EPS” on Page 23 for a reconciliation of adjusted EPS to EPS. 

Weighted average shares outstanding used to compute diluted earnings per share increaseddecreased from 16,065,41216,149,278 for the third quarter of 2021 to 16,133,069 for the thirdsecond quarter of 2022 as a resultto 16,143,686 for the second quarter of 2023. The decrease is attributable to stock option exercises since the thirdsecond quarter of 2021.2022 offset by a decrease in the average stock price used to compute diluted shares from $4.93 for the second quarter of 2022 to $4.52 for the second quarter of 2023. Accordingly, dilutive shares of 20,352 were added to basic weighted average shares for the 2022 period compared to 2,334 for the 2023 period.

19

 

Nine-MonthSix-Month Periods Ended SeptemberJune 30, 20222023 and SeptemberJune 30, 20212022

 

Revenues.  Consolidated revenues for the nine-monthsix-month period ended SeptemberJune 30, 20222023 were $95,733,$74,608, an increase of $21,229,$12,109, or 28.5%19.4%, over $74,504$62,499 for the nine-monthsix-month period ended SeptemberJune 30, 2021.2022.  Overall, government/defense sales increased $10,216 or 67.1% and commercial sales increased 49.5% while government/defense sales decreased 7.2% from the 2021 period. Revenues for the 2022 period include the operations of Excell which was acquired by$1,893 or 4.0% .  On January 25, 2023, the Company experienced a ransomware cyberattack which impacted our ability to process orders, ship products, provide services to our customers and effectively manage our sales and operating planning process over a several week period for our Newark, NY location and an even longer period for our Virginia Beach, VA location. A large portion of our time during the quarter was devoted to data restoration, systems security augmentation, and regulatory reporting of the cyberattack, all of which were successfully accomplished with no ransom paid.  Management continues to work on December 13, 2021.its cybersecurity insurance claim covering the cost of engaging external cybersecurity experts and the business interruption impact.

 

Battery & Energy Products revenues increased $22,879,$3,041, or 35.2%5.1%, from $64,994$59,290 for the nine-monthsix-month period ended SeptemberJune 30, 20212022 to $87,873$62,331 for the nine-monthsix-month period ended SeptemberJune 30, 2022.2023.  The increase was attributable to the $19,898 revenue contribution from the operations of Excell, and a 7.1%$1,893 or 4.0% increase in commercial sales excluding Excell, partially offset byand a 1.9% reduction$1,148 or 9.6% increase in government/defense sales.  The increase in commercial sales excluding Excell, was driven by a 11.0%$3,601 or 19.5% increase in oil & gas market sales reflecting the recent rebound in the energy sector a 9.6% increase in industrial market sales including our new Thionyl Chloride and thin cell battery cells, and a $597 or 3.9% increase in medical battery sales due to the high demand for our batteries used in ventilators, respirators, infusion pumps and other medical devices. The declineThese increases in government/defensecommercial sales waswere partially offset by a $2,305 or 16.9% decrease in industrial and other commercial market sales primarily due to supply chain disruptions experienced internallytiming of demand for 9-Volt and by our customersnew Thionyl Chloride and thin cell battery cells which pushed out salesare expected to rebound in future periods. 

 

Communications Systems revenues decreased $1,650,increased $9,068, or 17.4%282.6%, from $9,510$3,209 for the nine-monthsix-month period ended SeptemberJune 30, 20212022 to $7,860$12,277 for the nine-monthsix-month period ended SeptemberJune 30, 2022.2023. This decrease isincrease was primarily attributable to supply chain disruptions including extended lead timesshipments of vehicle-amplifier adaptor orders to a global defense contractor for components causing delays in our shipmentsthe U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to customers, and the push out of certain orders by our customers to future periods. a major international defense contractor for an ongoing allied country government/defense modernization program.

 

Cost of Products Sold / Gross Profit.  Consolidated costCost of products sold totaled $74,414$56,584 for the nine-monthsix-month period ended SeptemberJune 30, 2022,2023, an increase of $19,263,$8,689, or 34.9%18.1%, from the $55,151$47,895 reported for the same nine-monthsix-month period a year ago. Consolidated cost of products sold as a percentage of total revenue increaseddecreased from 74.0%76.6% for the nine-monthsix-month period ended SeptemberJune 30, 20212022 to 77.7%75.8% for the nine-monthsix-month period ended SeptemberJune 30, 2022.2023. Correspondingly, consolidated gross margin decreasedincreased from 26.0%23.4% for the nine-monthsix-month period ended SeptemberJune 30, 2021,2022, to 22.3%24.2% for the nine-monthsix-month period ended SeptemberJune 30, 2022,2023, primarily reflecting lowerhigher factory volume and favorable product mix for our Communications Systems segment, incremental costs in 2022 associated with supply chain disruptions, including rapidtempered by the inefficiencies experienced at our Newark, NY and continuous increases inVirginia Beach, VA facilities resulting from the cost of some key components, manufacturing inefficiencies caused by component availability, extended lead times and logistical delays impacting timely deliveries, and the transition of new products to higher volume production.January 2023 cyberattack. 

 

For our Battery & Energy Products segment, gross profit for the first ninesix months of 20222023 was $19,217,$14,055, an increase of $2,973$183 or 18.3%1.3% over gross profit of $16,244$13,872 for the comparable 20212022 period. Battery & Energy Products’ gross margin of 21.9%22.5% decreased by 31090 basis points from the 25.0%23.4% gross margin for the year-earlier period, primarily reflecting rapid cost inflation on components not fully aligned with customer price increases, manufacturinglingering supply chain disruptions, inefficiencies associated with component availability, lead timesresulting from the January 2023 cyberattack, disposition of certain non-conforming materials and related logistics impacting timely deliveries, and incremental costs associated withcontinued investments in the transition of new products to higherhigh volume production.production, partially offset by improved price realization.

 

For our Communications Systems segment, gross profit for the first ninesix months of 20222023 was $2,102$3,969 or 26.7%32.3% of revenues, compared to gross profit of $3,109$732 or 32.7%22.8% of revenues, for the comparable 20212022 period. The declineincrease was primarily due to lowerhigher factory volume resulting in the under-absorption of factory costs and unfavorable salesfavorable product mix experienced during the first nine months of 2022.compared to last year’s second quarter.

24

 

Operating Expenses. Consolidated operatingOperating expenses for the nine-monthsix-month period ended SeptemberJune 30, 20222023 were $21,407,$14,333, an increase of $3,318$227 or 18.3%1.6% from the $18,089$14,106 for the nine-monthsix-month period ended SeptemberJune 30, 2021.2022.  The increase is primarily attributable to increased new product development investments and the acquisitionrecording of Excell, which contributed operatingthe $100 deductible on our cybersecurity insurance policy for expenses of $3,258 forincurred associated with the first nine months of 2022, including $545 of intangible asset amortization and one-time acquisition costs of $70.  Excluding Excell, operating expenses increased $60 or 0.3%.January 2023 cyberattack.  Both periods reflected continued tight control over discretionary spending.

 

Overall, operating expenses as a percentage of revenues were 22.4%19.2% for the nine-monthsix-month period ended SeptemberJune 30, 20222023 compared to 24.3%22.6% for the nine-monthsix-month period ended SeptemberJune 30, 2021.2022.  Amortization expense associated with intangible assets related to our acquisitions was $969$436 for the first ninesix months of 20222023 ($895388 in selling, general and administrative expenses and $74$48 in research and development costs), compared with $458$651 for the first ninesix months of 20212022 ($365600 in selling, general, and administrative expenses and $93$51 in research and development costs). Research and development costs were $5,425$3,810 for the nine-monthsix-month period ended SeptemberJune 30, 2022,2023, an increase of $202$281 or 3.9%8.0%, from $5,223$3,529 for the nine-monthssix-months ended SeptemberJune 30, 2021.2022. The increase is largely attributable to an increase in new product development in our acquisition of Excell.Communications Systems business to pursue both government/defense major programs and commercial opportunities. Selling, general, and administrative expenses increased $3,116 or 24.2%, to $15,982were essentially flat year over year, decreasing from $10,577 for the first ninesix months of 2022 from $12,866to $10,523 for the comparable 2021 period. The increase is attributable to the December 2021 acquisitionfirst six months of Excell which contributed $3,0112023, a decrease of selling, general and administrative expenses, including intangible asset amortization of $545, for the 2022 period.$54 or 0.05%. 

20

 

Other (Income) Expense.Income (Expense). Other income (expense) totaled $22$564 for the nine-monthsix-month period ended SeptemberJune 30, 20222023 compared to other expense of $76($232) for the nine-monthsix-month period ended SeptemberJune 30, 2021.2022.  Other income for the 2023 period includes an Employee Retention Credit for $1,544 under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act which was filed with the Internal Revenue Service during the second quarter of 2023. Interest and financing expense increased $419,$553, or 255.5%177.8%, from $164($311) for the first ninesix months of 20212022 to $583($864) for the first nine months of 2022.comparable period in 2023. The increase is primarily due to the financing of our acquisition of Excell in December 2021, working capital funding resulting from our January 2023 cyberattack and rising interest rates. Excluding the Excell Acquisition. MiscellaneousERC gain in the 2023 period, miscellaneous income (expense) amounted to $605($116) for the first nine months of 20222023 period compared with $88to $79 for the 20212022 period, primarily representingattributable to foreign exchange gains and loss due to fluctuations in foreign currency exchange gains on U.S.-denominated transactions and balances of our non-U.S. businesses.rates.

 

Income Taxes. ForThe income tax provision for the nine-month2023 six-month period ended September 30, 2022, Ultralife recognizedwas $1,242 compared to an income tax benefit of $171,($81) for the 2022 six-month period. Our effective tax rate increased to 29.2% for the 2023 period as compared to (30.5%) for the 2022 period, primarily attributable to the magnitude of our income reported in the first six-months of 2023, including the Employee Retention Credit, and the geographic mix of our operating results.  The income tax provision for the first six months of  2023 is comprised of a $512$354 current provision for income taxes expected to be paid on income primarily from our non-U.S. operations,in foreign jurisdictions, representing a cash-based effective tax rate of 8.3%, and a $683an $888 deferred benefit, compared to antax provision which primarily represents non-cash charges for U.S. taxes that will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  For the comparable 2022 period, the income tax provision of $290 for the prior year same period,benefit was comprised of a $163$294 current tax provision, andrepresenting a $127 deferred provision. Ourcash-based effective tax rate was 259.1% forof 110.5%, and a ($375) deferred tax benefit.  The period over period change in the first nine months of 2022 as compared to 24.4% for the first nine months of 2021cash-based effective tax rate is primarily attributable to the geographic mix of our operating results, including income generated in Canada by Excell and the larger effect of permanent and discrete adjustments for the current year.results. See Note 76 to the consolidated financial statements in Item 1 of Part I of this Form 10-Q for further information.additional information regarding our income taxes.

 

Net Income Attributable to Ultralife. Net income attributable to Ultralife was $105,$2,994, or $0.01$0.19 per share – basic and diluted on a GAAP basis for the six-month period ended June 30, 2023, compared to $344, or $0.02 per share – basic and diluted, for the nine-monthsix-month period ended SeptemberJune 30, 2022,2022. Adjusted EPS was $0.24 on a diluted basis for the 2023 period, compared to $897, or $0.06 per share – basic and diluted,$0.00 for the nine-month period ended September 30, 2021. 2022 period. Adjusted EPS excludes the provision (benefit) for deferred taxes of $888 and ($375) for the 2023 and 2022 periods, respectively, which primarily represents non-cash charges (benefits) for U.S. taxes that will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.  See the section “Adjusted EPS” on Page 23 for a reconciliation of adjusted EPS to EPS. 

Weighted average shares outstanding used to compute diluted earnings per share decreased from 16,199,69316,141,083 for the 2021 periodfirst six-months of 2022 to 16,144,16516,140,528 for the 2022 period.first six-months of 2023. The decrease is attributable to stock option exercises since the thirdsecond quarter of 20212022 offset by the anti-dilutive effect of thea decrease in the average stock price used to compute diluted shares from $7.94$5.11 for the first nine months of 2021six-month period ended June 30, 2022 to $5.00$4.25 for the first nine monthssix-month period ended June 30, 2023. Accordingly diluted shares of 2022. Accordingly, potential common24,751 were added to basic weighted average shares usedin 2022 compared to compute diluted earnings per share decreased from 179,951 for the 2021 period to 22,203 for the 2022 period.2,157 in 2023.

 


 

Adjusted EBITDA

 

In evaluating our business, we consider and use Adjustedadjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance. We define Adjustedadjusted EBITDA as net income (loss) attributable to Ultralife before interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We also use Adjustedadjusted EBITDA as a supplemental measure to review and assess our operating performance and to enhance comparability between periods. We believe the use of Adjustedadjusted EBITDA facilitates investors’ understanding of operating performance from period to period by backing out potential differences caused by variations in such items as capital structures (affecting relative interest expense and stock-based compensation expense), the amortization of intangible assets acquired through our business acquisitions (affecting relative amortization expense and provision (benefit) for income taxes), the age and book value of facilities and equipment (affecting relative depreciation expense) and one-time charges/benefits relating to income taxes. We also present Adjustedadjusted EBITDA from operations because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We reconcile Adjustedadjusted EBITDA to net income (loss) attributable to Ultralife Corporation, the most comparable financial measure under GAAP.

 

We use Adjustedadjusted EBITDA in our decision-making processes relating to the operation of our business together with GAAP financial measures such as operating income (loss). We believe that Adjustedadjusted EBITDA permits a comparative assessment of our operating performance, relative to our performance based on our GAAP results, while isolatingeliminating the effects of depreciation and amortization, which may vary from period to period without any correlation to underlying operating performance, and of stock-based compensation, which is a non-cash expense that varies widely among companies. We believe that by presenting Adjustedadjusted EBITDA, we assist investors in gaining a better understanding of our business on a going forward basis. We provide information relating to our Adjustedadjusted EBITDA so that securities analysts, investors and other interested parties have the same data that we employ in assessing our overall operations. We believe that trends in our Adjustedadjusted EBITDA are a valuable indicator of our operating performance on a consolidated basis and of our ability to produce operating cash flows to fund working capital needs, to service debt obligations and to fund capital expenditures.

 

21

The term Adjustedadjusted EBITDA is not defined under GAAP and is not a measure of operating income (loss), operating performance or liquidity presented in accordance with GAAP. Our Adjustedadjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, Adjustedadjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) attributable to Ultralife Corporation or other consolidated statement of operations data prepared in accordance with GAAP. Some of these limitations include, but are not limited to, the following:

 

 

Adjusted EBITDA does not reflect (1) our cash expenditures or future requirements for capital expenditures or contractual commitments; (2) changes in, or cash requirements for, our working capital needs; (3) the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; (4) income taxes or the cash requirements for any tax payments; and (5) all of the costs associated with operating our business;

 

 

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and Adjustedadjusted EBITDA from continuing operations does not reflect any cash requirements for such replacements;

 

 

While stock-based compensation is a component of cost of products sold and operating expenses, the impact on our consolidated financial statements compared to other companies can vary significantly due to such factors as assumed life of the stock-based awards and assumed volatility of our common stock; and

 

 

Other companies may calculate Adjustedadjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

 

We compensate for these limitations by relying primarily on our GAAP results and using Adjustedadjusted EBITDA only on a supplemental basis. Neither current nor potential investors in our securities should rely on Adjustedadjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of Adjustedadjusted EBITDA to net income (loss)loss attributable to Ultralife.


 

Adjusted EBITDA is calculated as follows for the periods presented:

 

  

Three-Month Period Ended

  

Nine-Month Period Ended

 
  

September 30,

  

September 30,

  

September 30,

  

September 30,

 
  

2022

  

2021

  

2022

  

2021

 
                 

Net (loss) income attributable to Ultralife Corporation

 $(239) $(585) $105  $897 

Add:

                

Interest and financing expense

  272   53   583   164 

Income tax (benefit) provision

  (90)  (175)  (171)  290 

Depreciation expense

  815   700   2,450   2,160 

Amortization expense

  318   148   969   458 

Stock-based compensation expense

  179   142   552   512 

Non-cash purchase accounting adjustments

  -   -   55   - 

Adjusted EBITDA

 $1,255  $283  $4,543  $4,481 

  

Three-Month Period Ended

  

Six-Month Period Ended

 
  

June 30,

  

June 30,

  

June 30,

  

June 30,

 
  

2023

  

2022

  

2023

  

2022

 
                 

Net income attributable to Ultralife Corporation

 $3,340  $512  $2,994  $344 

Add:

                

Interest expense

  440   177   864   311 

Income tax provision (benefit)

  1,375   170   1,242   (81)

Depreciation expense

  760   819   1,522   1,635 

Amortization expense

  227   323   436   651 

Stock-based compensation expense

  154   184   293   373 
Cybersecurity insurance policy deductible  -   -   100   - 

Non-cash purchase accounting adjustments

  -   -   -   55 

Adjusted EBITDA

 $6,296  $2,185  $7,451  $3,288 


Adjusted Earnings Per Share

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis.  We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future.  We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP.  Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

Adjusted EPS is calculated as follows for the periods presented:

  

Three-Month Period Ended

 
  

June 30, 2023

  

June 30, 2022

 
  

Amount

  

Per

Basic

Share

  

Per

Diluted

Share

  

Amount

  

Per

Basic

Share

  

Per

Diluted

Share

 

Net Income

 $3,340  $.21  $.21  $512  $.03  $.03 

Deferred Tax Provision

  1,278   .08   .08   27   -   - 

Adjusted Net Income

 $4,618  $.29  $.29  $539  $.03  $.03 
                         

Weighted Average Shares Outstanding

      16,141   16,144       16,129   16,149 

  

Six-Month Period Ended

 
  

June 30, 2023

  

June 30, 2022

 
  

Amount

  

Per

Basic

Share

  

Per

Diluted

Share

  

Amount

  

Per

Basic

Share

  

Per

Diluted

Share

 

Net Income

 $2,994  $.19  $.19  $344  $.02  $.02 

Deferred Tax Provision (Benefit)

  888   .05   .05   (375)  (.02)  (.02)

Adjusted Net Income (Loss)

 $3,882  $.24  $.24  $(31) $.00  $.00 
                         

Weighted Average Shares Outstanding

      16,138   16,141       16,116   16,141 

23

 

Liquidity and Capital Resources

 

As of SeptemberJune 30, 2022,2023, cash on hand totaled $5,051$8,283 (including restricted cash of $73)$81), a decreasean increase of $3,362$2,570 as compared to $8,413 as$5,713 of cash held at December 31, 2021,2022, primarily attributable to draws on our credit facility and net income generated during the procurement of inventory to enhance our ability to service orders requested by customers to ship in 2022 amidst challenging supply chain conditions.period.

 

During the nine-monthsix-month period ended SeptemberJune 30, 2022,2023, cash provided by our operations was $386, as compared to $3,400 used in operations was $3,827, as compared to $8,462 generated from operations for the nine-monthsix-month period ended SeptemberJune 30, 2021.2022.  For the 20222023 period, we used cash provided by our operations was comprised of $8,714 to procurenet income of $3,013 plus non-cash items totaling $3,171 for depreciation, amortization, stock-based compensation, and deferred taxes, largely offset by a $5,798 increase in net working capital. The increase in working capital was driven by the procurement of inventory to proactively manage our supply chain, reduce lead times and the impact of potential cost increases on components and raw materials, and enhance our position to service customer orders.  The increase in inventory andorders, as well as the timingeffects of sales, collections and disbursements resulted in net cash of $7,245 used for working capital, which was partially offset by net income of $105 and non-cash net expenses totaling $3,313 for depreciation, amortization, stock-based compensation, and deferred taxes.the January 2023 cyberattack.

 

Cash used in investing activities for the ninesix months ended SeptemberJune 30, 20222023 was $1,396$1,013 for capital expenditures, primarily reflecting investments in equipment for new products transitioning to high-volume manufacturing. 

 

Cash provided by financing activities for the ninesix months ended SeptemberJune 30, 20222023 was $2,097, primarily consisting of$3,362, largely attributable to draws fromon our credit facility forprimarily due to the sales impact of the January 2023 cyberattack as well as the advance purchase of certain critical raw materials, requiring cash-in-advance payment terms by the vendors, plus $105 in net proceeds on stock-based awards, partially offset by $1,333 of principle payments on our term loan.loan during the period.

 

We continue to have significant U.S. net operating loss carryforwards available to utilize as an offset to future taxable income. See Note 76 to the consolidated financial statements of this Form 10-Q for additional information.

 

Going forward, we expect positive operating cash flow and the availability under our Revolving Credit Facility will be sufficient to meet our general funding requirements for the foreseeable future.

 

To provide flexibility in accessing the capital market, the Company filed a shelf registration statement on Form S-3 on March 30, 2021, which was declared effective by the SEC on April 2, 2021. Under this registration statement, upon the filing of an appropriate supplemental prospectus, we may offer and sell certain of our securities from time to time in one (1) or more offerings, at our discretion, of up to an aggregate offering price of $100 million. We intend to use the net proceeds resulting from any sales of our securities for general corporate purposes which may include, but are not limited to, potential acquisitions of complementary businesses or technologies, strategic capital expenditures to expand and protect our competitive position, and investments in the development of transformational, competitively-differentiated products for attractive growth markets.

 


 

Commitments

 

As of SeptemberJune 30, 2022,2023, the Company had $14,330$17,630 outstanding borrowings on the Revolving Credit Facility and $8,667$7,167 on the Term Loan Facility. The Company was in full compliance with all covenants under the Credit Facilities as of SeptemberJune 30, 2022.2023.

 

As of SeptemberJune 30, 2022,2023, we had made commitments to purchase approximately $624$1,023 of production machinery and equipment.

 

 

Critical Accounting Policies

 

Management exercises judgment in making important decisions pertaining to choosing and applying accounting policies and methodologies in many areas.  Not only are these decisions necessary to comply with GAAP, but they also reflect management’s view of the most appropriate manner in which to record and report our overall financial performance. All accounting policies are important, and all policies described in Note 1 to the consolidated financial statements in our 20212022 Annual Report on Form 10-K and Note 1 to the consolidated financial statements in Part I of thissubsequent Quarterly Reports on Form 10-Q should be reviewed for a greater understanding of how our financial performance is recorded and reported.

 

During the first ninesix months of 2022,2023, there were no significant changes in the manner in which our significant accounting policies were applied or in which related assumptions and estimates were developed.

 


24

 

Item 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our President and Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer and Treasurer (Principal Financial Officer) have evaluated our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e)) as of the end of the period covered by this quarterly report. Based on this evaluation, our President and Chief Executive Officer and Chief Financial Officer and Treasurer concluded that our disclosure controls and procedures were effective as of such date.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting (as defined in Securities Exchange Act Rule 13a-15(f)) that occurred during the fiscal quarter covered by this quarterly report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 


 

PART II.         OTHER INFORMATION

Item 1A.Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

In addition to the Risk Factors set forth in Item 1A of our Form 10-K for the year ended December 31, 2021, as filed on March 8, 2022, you should carefully consider the following Risk Factors that we believe are material to our business:

Changes in economic conditions, including inflation, rising interest rates, volatile equity capital markets and ongoing supply chain disruptions, have affected and may continue to affect our business, revenues and earnings adversely.

Inflation rates have increased and may continue to rise. Our suppliers have raised their prices and may continue to raise prices that we may not be able to pass on to our customers on a timely manner consistent with the price increases. This affected and may continue to affect our business and profit margins adversely.

Rising interest rates will increase the cost of our variable borrowing rates, may affect our earnings adversely.

 

Item 6.Exhibits

 

Exhibit

Index

 

Exhibit Description

 

Incorporated by Reference from

31.1

 

Rule 13a-14(a) / 15d-14(a) CEO Certifications

 

Filed herewith

31.2

 

Rule 13a-14(a) / 15d-14(a) CFO Certifications

 

Filed herewith

32

 

Section 1350 Certifications

 

Furnished herewith

101.INS

 

Inline XBRL Instance Document

 

Filed herewith

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

Filed herewith

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

Filed herewith

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

Filed herewith

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

Filed herewith

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

Filed herewith

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

Filed herewith

 

Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of SeptemberJune 30, 20222023 and December 31, 2021,2022, (ii) Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the three and ninesix months ended SeptemberJune 30, 20222023 and 2021,2022, (iii) Consolidated Statements of Cash Flows for the ninesix months ended SeptemberJune 30, 20222023 and 2021,2022, (iv) Consolidated Statements of Changes in Stockholders’Shareholders’ Equity for the three and ninesix months ended SeptemberJune 30, 20222023 and 2021,2022, and (v) Notes to Consolidated Financial Statements.

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

ULTRALIFE CORPORATION

 

(Registrant)

 

Date: July 27, 2023

By:

/s/

Michael E. Manna

Date: October 27, 2022Michael E. Manna

By:

/s/ Michael D. Popielec

 Michael D. Popielec

President and Chief Executive Officer

   (Principal

(Principal Executive Officer)

 
    
    

Date: OctoberJuly 27, 20222023

By:

/s/

Philip A. Fain

 
   

Philip A. Fain

 
   

Chief Financial Officer and Treasurer

 
   (Principal

(Principal Financial Officer and

 
   

Principal Accounting Officer)

 

 

3127